An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Varicella Zoster Virus Infection Clinical Trial

Official title:
An Open-label, Bridging Study to Assess the Safety and Immunogenicity of BARYCELA Inj. (Live Attenuated Varicella Vaccine for Injection) in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Status Not yet recruiting

Clinical Trial Summary

The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: - Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) - Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05664152
Study type	Interventional
Source	GC Biopharma Corp
Contact
Status	Not yet recruiting
Phase	N/A
Start date	February 2023
Completion date	June 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01682109` - Palatability Testing of a New Paediatric Formulation of Valacyclovir	Phase 4
Recruiting	`NCT05198570` - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting	`NCT05604911` - Herpes Virus Infections in Kidney Transplant Patients
Recruiting	`NCT05532540` - Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study
Completed	`NCT01689285` - Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir	Phase 1
Terminated	`NCT04081480` - Pharmacokinetics of Valacyclovir Oral Solution in Children	N/A
Recruiting	`NCT04403139` - VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination	Phase 4